Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2016-09-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
募集资金置换专项审核报告
Regulatory Filings
2016-09-13 Chinese
内幕交易知情人登记管理制度
Regulatory Filings Classification · 95% confidence The document is a detailed internal policy titled '内幕交易知情人登记管理制度' (Insider Trading Insider Registration Management System) issued by 郑州安图生物工程股份有限公司. It outlines the rules, responsibilities, and procedures for managing insider information and insider registration within the company. The content focuses on compliance with securities laws, insider information definitions, confidentiality obligations, and reporting requirements to regulatory bodies. There is no indication that this is a financial report, earnings release, or any form of shareholder meeting material. It is a regulatory compliance document related to insider trading management and internal governance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance documents and regulatory announcements that do not fit other specific categories.
2016-09-13 Chinese
内幕交易知情人登记管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '内幕交易知情人登记管理制度' (Insider Trading Insider Registration Management System) issued by the company. It outlines the rules, responsibilities, and procedures for managing insider information and insider personnel registration to comply with securities laws and stock exchange regulations. The content focuses on governance, compliance, and internal control related to insider trading and information disclosure. There are no financial statements, earnings data, or report publication announcements. It is not a report of financial results, audit, or capital changes. The document is a governance-related internal regulation concerning insider information management and compliance with securities laws. Therefore, the most appropriate classification is Governance Information (CGR).
2016-09-13 Chinese
招商证券股份有限公司关于郑州安图生物工程股份有限公司以募集资金置换预先已投入募集资金投资项目的自筹资金之核查意见
Regulatory Filings
2016-09-13 Chinese
募集资金置换专项审核报告
Regulatory Filings
2016-09-13 Chinese
使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of idle self-owned funds for cash management. It details the board's approval of investing up to 680 million RMB in low-risk financial products for up to 12 months. The document includes information about the investment types, risk control measures, and the independent directors' opinions. It is a specific corporate announcement about financing activities related to cash management and investment of idle funds, not a full financial report, earnings release, or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on a financing-related announcement, not a full report or regulatory filing.
2016-09-13 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.